Table 2 Baseline clinical characteristics of the female study population

Age (years) median (IQR)

57 (54–60)

55 (53–62)

74 (68–81)

0.9999

<0.0001

<0.0001

Length of stay (days), median (IQR)

7 (6–7)

25 (20.0–33.0)

15 (8–19)

<0.0001

0.0033

0.0003

Comorbidity, n° (%)

89 (61.38)

47 (61.84)

22 (81.48)

0.9999

0.0503

0.0942

 Hypertension

43 (29.65)

20 (26.31)

14 (51.85)

0.6408

0.0431

0.0190

 Diabetes

20 (13.79)

6 (7.89)

2 (7.41)

0.2719

0.5343

>0.9999

 Cancer

9 (6.21)

5 (6.58)

4 (14.81)

0.9999

0.1259

0.2366

 Cardiovascular diseases

11 (7.58)

5 (6.58)

3 (11.11)

0.9999

0.4637

0.4290

 Chronic Lung diseases

12 (8.27)

8 (10.53)

6 (22.22)

0.6249

0.0413

0.1877

 Obesity-Dyslipidaemia

43 (29.65)

28 (36.84)

8 (29.63)

0.2916

0.9999

0.6396

 Chronic Kidney disease

5 (3.49)

2 (2.63)

2 (7.41)

0.9999

0.3024

0.2805

 Others

20 (13.79)

11 (14.47)

5 (18.52)

0.9999

0.5453

0.5461

 Leucocytes n°

5.95 (5.40–6.81)

6.28 (5.46–7.02)

7.29 (5.74–9.07)

0.9999

0.2849

0.6427

 Lymphocytes n°

1.18 (1.04–1.27)

1.00 (0.84–1.12)

0.89 (0.74–1.21)

0.0008

0.0349

0.9999

 Lymphocytes %

19.76 (17.96–22.16)

15.65 (16.62–18.58)

13.40 (9.59–19.18)

0.0009

0.0025

0.9999

 Neutrophils n°

4.02 (3.6–4.78)

4.88 (4.23–5.43)

5.83 (4.37–7.66)

0.2125

0.0649

0.9426

 Interleukine-6

34.21 (26.81–38.60)

75.30 (50.26–86.23)

65.36 (45.03–154.6)

<0.0001

<0.0001

0.9999

 C-reactive protein

8.38 (4.78–10.44)

12.67 (10.44–14.99)

14.47 (6.43–21.89)

0.0042

0.0846

0.9999

 LDH

304 (289.0–345.0)

420.0 (380.0–486.0)

415.0 (283.0–539.0)

<0.0001

0.0855

0.9999

 D-Dimer

258.0 (228.0–275.0)

334.0 (258.0–422.0)

269.0 (207.0–424.0)

0.0379

0.7287

0.9999

 Ferritin

378.0 (284.0–437.0)

528.0 (445.0–729.0)

445.0 (387.0–730.0)

0.0023

0.3007

0.9999